Investor Relations

Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.

News Releases

Date Title and Summary
Toggle Summary NICE Recommends the Use of gammaCore for the Treatment of Cluster Headache in the NHS
NICE has today published a medical technologies guidance document recommending the use of gammaCore within the NHS for the acute and preventive treatment of cluster headache in the U.K. LONDON and BASKING RIDGE, N.J. , Dec. 03, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a
Toggle Summary electroCore to Present at the Two December Investor Conferences
BASKING RIDGE, N.J. , Nov. 26, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Dan Goldberger , Chief Executive Officer, will present  a corporate overview and host investor meetings at the Evercore ISI HealthCONx 
Toggle Summary electroCore Announces Third Quarter 2019 Financial Results
Continued growth in prescribing physicians, paid months of therapy and dispensed prescriptions Company to host conference call and webcast today, November 13 , at 4:30pm ET BASKING RIDGE, N.J. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
Toggle Summary electroCore to Announce Third Quarter 2019 Financial Results on Wednesday, November 13th
Conference Call to be Held at 4:30pm Eastern Time BASKING RIDGE, N.J. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the third quarter and nine-months ended September 30,
Toggle Summary electroCore Appoints Medical Technology Veteran Daniel S. Goldberger as Chief Executive Officer
BASKING RIDGE, N.J. , Sept. 30, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Daniel S. Goldberger as Chief Executive Officer, effective October 1 . Mr.
Toggle Summary electroCore Provides Update on 510(k) Submission Seeking Expanded Indication for gammaCore™
Additional information requested by FDA; Premium 2 trial progressing as planned   BASKING RIDGE, N.J. , Sept. 25, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR, or the “Company”), a commercial-stage bioelectronic medicine company, today announced that the U.S.
Toggle Summary electroCore Announces Second Quarter 2019 Financial Results
Sequential growth reported in paid months of therapy, prescribing physicians and prescriptions dispensed Company to host conference call and webcast today, August 13 , at 4:30pm ET BASKING RIDGE, N.J. , Aug. 13, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc.
Toggle Summary electroCore Announces Distribution Agreement with Doctor’s Medical LLC to Expand Patient Access to gammaCore
BASKING RIDGE, N.J. , Aug. 12, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the company has entered into an exclusive contract with Doctor’s Medical, LLC for distribution rights to gammaCore for patients with workers’
Toggle Summary electroCore to Announce Second Quarter 2019 Financial Results on Tuesday, August 13
Conference Call to be Held at 4:30pm Eastern Time BASKING RIDGE, N.J. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the second quarter and six-months ended June 30, 2019
Toggle Summary electroCore Files Registration Statement on Form S-3
BASKING RIDGE, N.J. , July 15, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has filed a "universal shelf" registration statement on Form S-3 (the “Registration Statement”) with the Securities and Exchange